Resistance mutation info of drug

Drug General Information
Drug ID D04TMQ
Drug Name D-cycloserine Drug Info
Synonyms Cicloserina; Closerin; Closina; Cyclorin; Cycloserine; Cycloserinum; Farmiserina; Micoserina; Miroserina; Miroseryn; Novoserin; Orientomycin; Oxamicina; Oxamycin; Seromycin; Tebemicina; Tisomycin; Wasserina; Cicloserina [Italian]; Oxamicina [Italian]; C 3909; PA 94; Alpha-Cycloserine; C-9390; C-9400; Cicloserina [INN-Spanish]; Cycloserinum [INN-Latin]; D-CS; DRG-0195; I-1431; K-300; PA-94; SC-49088; Seromycin (TN); Cyclo-D-serine; Cycloserine [INN:BAN:JAN]; E-733-A; RO-1-9213; Cycloserine (JP15/USP/INN); D-amino-3-isoxazolidinone; D-(+)-Cycloserine; D-4-Amino-3-isossazolidone; D-4-Amino-3-isossazolidone [Italian]; D-4-amino-3-isoxazolidinone; D-4-amino-3-isoxazolidone; FA6C7F8B-D080-4EA3-978F-1ECFB5A29D09; R-(+)-Cycloserine; R-4-Amino-3-isoxazolidinone; R(+)-4-Amino-3-isoxazolidinone; (+)-4-Amino-3-isoxazolidinone; (+)-Cycloserine; (4R)-4-Amino-3-isoxazolidinone; (4R)-4-amino-1,2-oxazolidin-3-one; (4R)-4-aminoisoxazolidin-3-one; (R)-(+)-4-Amino-3-isoxazolidinone; (R)-(+)-Cycloserine; (R)-4-AMINO-ISOXAZOLIDIN-3-ONE; (R)-4-Amino-3-isoxazolidinone; (R)-4-Amino-3-isoxazolidone; (R)-Cycloserine; 3-Isoxazolidinone, 4-amino-, (+)-(8CI); 3-Isoxazolidinone, 4-amino-, (4R)-(9CI); 3-Isoxazolidinone, 4-amino-, (R); 3-Isoxazolidinone, 4-amino-, D
Drug Type Small molecular drug
Company Eli Lilly
Structure D04TMQ
Drug Resistance Mutations
Target Name Bacterial D-alanine racemase (alrA)
Gene Name alrA
Species Mycobacterium tuberculosis
Targeted Disease Tuberculosis
Drug Resistance Mutations
Mutation info Missense: S261A [1559220]
Mutation Prevalence 4.2% of isolates
Target Name Bacterial Probable D-serine/alanine/glycine transporter protein CycA (cycA)
Gene Name cycA
Uniprot ID O33203_MYCTU
Species Mycobacterium tuberculosis
Reference Sequence MPDDIAAADPTDTQPHLRRDLANRHIQLIAIGGAIGTGLFMGSGRTISLAGPAVMVVYGI
IGFFVFFVLRAMGELLLSNLNYKSFVDFAADLRGPAAGFFVGWSYWFAWVVTGIADLVAI
TGYARFWWPGLPIWVPALVTVALILAVNLFSVRHFGELEFWFALIKVAAIVCLIAVGAIL
VATNFVSPHGVHATIENLWNDNGFFPTGFLGVVSGFQIAFFAYIGVELVGTAAAETADPR
RTLPRAINAVPLRVAVFYIGALLAILAVVPWRQFASGESPFVTMFSLAGLAAAASVVNFV
VVTAAASSANSGFFSTGRMLFGLADEGHAPAAFHQLNRGGVPAPALLLTAPLLLTSIPLL
YAGRSVIGAFTLVTTVSSLLFMFVWAMIIISYLVYRRRHPQRHTDSVYKMPGGVVMCWAV
LVFFAFVIWTLTTETETATALAWFPLWFVLLAVGWLVTQRRQSRRSFGFHCQVVGVRQQL
GRGMARLAMKIHARPKLRSAVVVEPVSAGEPGARRSAKSVRKLASDDSQSAHCPVAVVGL
ADGGRDPQYHHDGPDR [Mycobacterium tuberculosis]
Targeted Disease Tuberculosis
Drug Resistance Mutations
Mutation info Missense: G318T [1559220]
Mutation Prevalence 12.5% of isolates
Mutation info Missense: G508T [1559220]
Mutation Prevalence 12.5% of isolates
Mutation info Missense: P188A [1559220]
Mutation Prevalence 12.5% of isolates
References
Ref 536854Has nature already identified all useful antibacterial targets? Curr Opin Microbiol. 2008 Oct;11(5):387-92. Epub 2008 Oct 6.
Ref 1559220[A preliminary study on the molecular characteristics of D-cycloserine resistance of Mycobacterium tuberculosis].Zhonghua Liu Xing Bing Xue Za Zhi.2017 Feb 10;38(2):240-243.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.